Bajaj Healthcare launches Magnesium L-Threonate in Nutraceutical segment; stock zooms ~4%

23 Feb 2022 , 02:35 PM

On Wednesday, Bajaj Healthcare Limited announced the launch of Magnesium L-Threonate in the Nutraceutical segment. Following this development, the company’s stock mounted 4.19% or Rs15.30 in today’s trade at Rs389.55, against its previous closing price of Rs373.90.

Bajaj Healthcare’s stock remained in the upper circuit today with an intraday high of Rs397.65 so far.

Magnesium L- Threonate is a nutritional supplement specifically used to normalize magnesium levels in the body, muscle, and nerve function, helps to improve memory and also helps in brain development by reversing brain aging. It controls, prevents, and normalizes the symptoms associated with Alzheimer’s disease, Bipolar disorder, Attention disorder, Parkinson’s disease etc. It also helps in improving the cognitive functions of the brain and preventing loss of synapses.

“Company is pleased to add Magnesium L-Threonate to its expanding product portfolio and continue to carry through, Bajaj’s commitment to deliver therapeutical products every year. BHL has the aim to produce 12-15 tons of Magnesium L-Threonate in Q4 FY22 and 120 tons in FY23,” commented on the launch of Magnesium L-Threonate, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare.